
Novo Nordisk pulls plug on two zilttivekimab trials after futility findings
Novo Nordisk has terminated two additional late-stage trials of its IL-6 inhibitor zilttivekimab after an independent data monitoring committee determined the studies were unlikely to meet their primary endpoints, marking another setback for the drug program.


